<PAGE>
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB

                                   (Mark One)

[X ]     QUARTERLY  REPORT  PURSUANT  TO SECTION  13 OR 15(d) OF THE  SECURITIES
         EXCHANGE ACT OF 1934

                  For the quarterly period ended June 30, 2003

                                       OR

[ ]      TRANSITION REPORT UNDER SECTION 13 OF 15(d) OF THE EXCHANGE ACT OF 1934

          From the transition period from ___________ to ____________.

                         Commission File Number 01-28911


                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
        -----------------------------------------------------------------
        (Exact name of small business issuer as specified in its charter)

                   Colorado                                91-1869677
------------------------------------------------      --------------------
(State or other jurisdiction of incorporation or         (IRS Employer
                 organization)                         Identification No.)


         20700 Ventura Boulevard, #227, Woodland Hills, California 91364
        -----------------------------------------------------------------
                    (Address of principal executive offices)

                                 (818) 227-9494
                          -------------------------------
                           (Issuer's telephone number)

                                       N/A
                                     -------
              (Former name, former address and former fiscal year,
                          if changed since last report)

         Indicate by check mark whether the registrant (1) filed all reports
required to be filed by Section 13 or 15(d) of the Exchange Act during the past
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days:
                                 Yes[ x ] No [ ]

As of August 8, 2003 7,855,500 shares of Common Stock of the issuer were
outstanding.


<PAGE>




PART I.  FINANCIAL INFORMATION

Item 1.  Financial Statements
                                       NATIONAL HEALTHCARE TECHNOLOGY, INC.
                                                  BALANCE SHEETS
<TABLE>
<CAPTION>


                                                                                   June 30,         September 30,
                                                                                     2003                2002
                                                                               -------------------------------------
                                                                                  (Unaudited)
<S>                                                                                    <C>                 <C>

ASSETS                                                                          $              -   $              -
                                                                                ================   ================

               LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)

Current liabilities:
  Accounts payable:
    Trade                                                                       $         57,364   $         42,889

    Crown Partners, Inc.                                                                  67,009   53,811

  Deposit on merger                                                                       18,304   18,304
                                                                                ----------------   ------

    Total current liabilities                                                            142,677   115,004
                                                                                ----------------   -------

Stockholders' equity (deficit):
  Preferred stock, $.01 par value, 500,000 shares

    authorized, no shares issued and outstanding                                               -   -
  Common stock, $.001 par value, 25,000,000 shares

    authorized:  7,855,500 shares issued and outstanding:                                  7,855   7,855

  Additional paid in capital                                                           1,237,439   1,237,439

  Deficit accumulated during the development stage                                    (1,387,971)  (1,360,298)
                                                                                ----------------   ----------

    Total stockholders' equity (deficit)                                                (142,677)  (115,004)
                                                                                ----------------   --------
                                                                                $              -   $              -
                                                                                ================   ================





</TABLE>





<PAGE>

<TABLE>
<CAPTION>

                                           NATIONAL HEALTHCARE TECHNOLOGY, INC.
                                                 STATEMENTS OF OPERATIONS
                                                       (Unaudited)

                                                                                                              Inception
                                        Three Months Ended                     Nine Months Ended               through
                                             June 30,                               June 30,                   June 30,
                                      2003               2002               2003               2002              2003
                                -----------------  -----------------   ----------------  -----------------  ---------------
<S>                                    <C>                 <C>                <C>               <C>              <C>

Revenue                         $             -    $             -     $             -   $             -    $         9,578

Expenses:
  Development costs                           -                  -                   -                 -          1,264,236
  General and administrative             11,426                790              27,673            32,827            130,113
                                ---------------    ---------------     ---------------   ---------------    ---------------
                                         11,426                790              27,673            32,827          1,394,349
                                ---------------    ---------------     ---------------   ---------------    ---------------

Net loss before income taxes            (11,426)              (790)            (27,673)          (32,827)        (1,384,771)

Income taxes                                  -                  -                   -                 -              3,200
                                ---------------    ---------------     ---------------   ---------------    ---------------

Net loss                        $       (11,426)   $          (790)    $       (27,673)  $       (32,827)   $    (1,387,971)
                                 ==============     ==============      ==============   ===============     ==============


Basic net loss per common share $          0.00)   $         (0.00)    $         (0.00)  $         (0.00)
                                 ==============     ==============      ==============   ===============

Weighted average shares
outstanding                           7,855,500          7,855,500           7,855,500         7,855,500
                                 ==============     ==============      ==============   ===============





</TABLE>
<PAGE>

<TABLE>
<CAPTION>
                                    NATIONAL HEALTHCARE TECHNOLOGY, INC.
                                              STATEMENTS OF CASH FLOWS
                                                    (Unaudited)
                                                                                                       Inception
                                                                        Nine Months Ended               through
                                                                            June 30,                    June 30,
                                                                            -------                     -------
                                                                     2003               2002              2003
                                                               ------------------ ----------------- -----------------

<S>                                                                     <C>                  <C>             <C>
Cash flows from operating activities:
  Net loss                                                     $        (27,673)  $        (32,827) $    (1,387,971)
    Adjustments to reconcile net loss to net cash
    provided by (used in) operating activities:
      Depreciation and amortization                                           -                  -           22,977
      Common stock issued for settlement of interest expense                  -                  -           12,900
      Common stock issued for services                                        -                  -          217,900
      Loss on abandoned assets                                                -                  -          120,387
      Gain on sale of assets                                                  -                  -             (500)
      Income from sale of abandoned assets                                    -                  -           (9,578)
  Changes in operating assets and liabilities
    Accounts payable                                                     27,673             32,827          125,176
    Deposit on merger                                                         -                  -           18,304
                                                               ----------------   ----------------  ---------------
        Net cash used in operating activities                                 -                  -         (880,405)
                                                               ----------------   ----------------  ---------------

Cash flows from investing activities:
  Purchase of property and equipment                                          -                  -          (87,314)
  Proceeds from the sale of equipment                                         -                  -           15,078
                                                               ----------------   ----------------  ---------------
        Net cash provided by (used in) investing activities                   -                  -          (72,236)
                                                               ----------------   ----------------  ---------------

Cash flows from financing activities:
  Proceeds from notes payable                                                 -                  -          217,200
  Payments on notes payable                                                   -                  -          (20,000)
  Proceeds from the sale of common stock, net                                 -                  -          755,441
                                                               ----------------   ----------------  ---------------
        Net cash provided by financing activities                             -                  -          952,641
                                                               ----------------   ----------------  ---------------

Net increase (decrease) in cash and cash equivalents                          -                  -                -
Cash and cash equivalents at beginning of period                              -                  -                -
                                                               ----------------   ----------------  ---------------
Cash and cash equivalents at end of period                     $              -   $              -  $             -
                                                               ================   ================  ===============


</TABLE>




<PAGE>




                      NATIONAL HEALTHCARE TECHNOLOGY, INC.
                 NOTES TO INTERIM CONDENSED FINANCIAL STATEMENTS
                                  June 30, 2003


Note 1:Presentation

The accompanying unaudited financial statements have been prepared in conformity
with the accounting principles stated in the audited financial statements for
the year ended September 30, 2002 and reflect all adjustments which are, in the
opinion of management, necessary for a fair statement of the financial position
as of June 30, 2003 and the results of operations for the periods presented.
These statements have not been audited but have been reviewed by the Company's
independent certified public accountants. The operating results for the interim
periods are not necessarily indicative of results for the full fiscal year.

The notes to the consolidated financial statements appearing in the Company's
Annual Report as filed on SEC Form 10-KSB for the year ended September 30, 2002
should be read in conjunction with this Quarterly Report on Form 10-QSB.

<PAGE>




Item 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS


This report contains forward looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended and Section 21E of the Securities
Exchange Act of 1934, as amended. The Company's actual results could differ
materially from those set forth on the forward looking statements as a result of
the risks set forth in the Company's filings with the Securities and Exchange
Commission, general economic conditions, and changes in the assumptions used in
making such forward looking statements.

GENERAL

National Healthcare Technology, Inc. (the "Company") was organized February 29,
1996 as "Patriot Holding Corporation" and subsequently changed its name to
"National Healthcare Technology, Inc." on August 26, 1996. Between 1996 and
1999, the Company was unsuccessful in raising sufficient capital to begin and
complete a proposed double-blind study of an intravenous drug called Magkelate.
The Company did raise $1,000,000 which was used to pay its operating expenses
and general and administrative expenses as well as expenses related to starting
the double-blind study. Following its inability to raise capital and needing to
conserve its financial resources, the Company dismissed all of its employees in
early 1999. The developer of Magkelate passed away in the fall of 1999 and the
Magkelate patent has expired. Since 1999, the Company has been substantially
inactive. The Company is in the development stage as defined in Statement of
Financial Accounting Standards No. 7.

When used in this Form 10-QSB, the words "anticipate", "estimate", "expect",
"project" and similar expressions are intended to identify forward-looking
statements. Such statements are subject to certain risks, uncertainties and
assumptions including the possibility that the Company's proposed plan of
operation will fail to generate projected revenues. Should one or more of these
risks or uncertainties materialize, or should underlying assumptions prove
incorrect, actual results may vary materially from those anticipated, estimated
or projected.

LIQUIDITY AND CAPITAL RESOURCES

The Company is in the development stage and since inception has experienced no
significant change in liquidity or capital resources or stockholders equity
other than the receipt of $1,000,000 from an offering conducted under Rule 504
of Regulation D in 1997. The Company's balance sheet as of June 30, 2003
reflects no assets and limited liabilities. Further, there exists no agreements
or understandings with regard to loan agreements by or with the Officers,
Directors, principals, affiliates or shareholders of the Company.

The Company is continuing to search for suitable merger candidates or other
businesses to become involved in so that it can commence operations and generate
revenues to continue paying its bills.

The Company will attempt to carry out its plan of business and hopes to enter
into a business combination with another entity. The Company cannot predict to
what extent its lack of liquidity and capital resources will hinder its business
plan prior to the consummation of a business combination.


RESULTS OF OPERATIONS

During the period from November 5, 1989 (inception) through September 30, 2003,
the Company engaged in limited operations and attempted to initiate its double
blind study of its drug, Magkelate. The Company received no revenues during this
period. The capital raised was expended for general office and administrative
expenses and the proposed double-blind study of Magkelate, which double-blind
study the Company was unable to start due to lack of capital.

For the nine months ended June 30, 2003, the Company had no revenue and its
expenses were $27,673 resulting in a net loss for the nine months of $27,673
compared to no revenue and expenses of $32,827 for the nine months ended June

<PAGE>

30, 2002 and a net loss of $32,827 for the nine months then ended.

For the three months ended June 30, 2003, the Company had no revenue and its
expenses were $11,426 resulting in a net loss for the quarter of $11,426
compared to no revenue and expenses of $790 for the three months ended June 30,
2002 and a net loss of $790.

The Company anticipates that until a business combination is completed with an
acquisition candidate, it will not generate revenue and may operate at a loss
after completing a business combination, depending upon the performance of the
acquired business. The Company will attempt to carry out its business plan as
discussed above. The Company cannot predict to what extent its lack of liquidity
and capital resources will hinder its business plan prior to the consummation of
a business combination.


NEED FOR ADDITIONAL FINANCING

The Company's existing capital will not be sufficient to meet the Company's cash
needs, including the costs of compliance with the continuing reporting
requirements of the Securities Exchange Act of 1934, as amended. Once a business
combination is completed, the Company's need for additional financing is likely
to increase substantially.
 No commitments to provide additional funds have been made by management or
other stockholders. Accordingly, there can be no assurance that any funds will
be available to the Company to allow it to cover its expenses.

The Company might seek to compensate providers of services by issuances of stock
in lieu of cash.


DESCRIPTION OF PROPERTIES

The Company presently has no office space.


EMPLOYEES

As of June 30, 2003, the Company had no employees.


New Accounting Pronouncements

In April 2002, the FASB approved for issuance Statements of Financial Accounting
Standards No. 145, "Rescission of FASB Statements No. 4, 44 and 64, Amendment of
SFAS 13, and Technical Corrections" ("SFAS 145"). SFAS 145 rescinds previous
accounting guidance, which required all gains and losses from extinguishment of
debt be classified as an extraordinary item. Under SFAS 145 classification of
debt extinguishment depends on the facts and circumstances of the transaction.
SFAS 145 is effective for fiscal years beginning after May 15, 2002 and is not
expected to have a material effect on the Company's financial position or
results of its operations.

 In July 2002, the FASB issued Statements of Financial Accounting Standards No.
146, "Accounting for Costs Associated with Exit or Disposal Activities" (SFAS
146). SFAS 146 requires companies to recognize costs associated with exit or
disposal activities when they are incurred rather than at the date of a
commitment to an exit or disposal plan. Examples of costs covered by SFAS 146
include lease termination costs and certain employee severance costs that are
associated with a restructuring, discontinued operation, plant closing, or other
exit or disposal activity. SFAS 146 is to be applied prospectively to exit or
disposal activities initiated after December 31, 2002. The adoption of SFAS 146
is not expected to have a material effect on the Company's financial position or
results of its operations.

<PAGE>

In December 2002, the FASB issued Statements of Financial Accounting Standards
No. 148 "Accounting for Stock-Based Compensation--Transition and Disclosure--an
amendment of FASB Statement No. 123, This Statement amends FASB Statement No.
123, Accounting for Stock-Based Compensation, to provide alternative methods of
transition for a voluntary change to the fair value based method of accounting
for stock-based employee compensation. In addition, this Statement amends the
disclosure requirements of Statement 123 to require prominent disclosures in
both annual and interim financial statements about the method of accounting for
stock-based employee compensation and the effect of the method used on reported
results. The adoption of SFAS 148 is not expected to have a material effect on
the Company's financial position or results of its operations.

Inflation

The Company's results of operations have not been affected by inflation and
management does not expect inflation to have a significant effect on its
operations in the future.


ITEM 3.   CONTROLS AND PROCEDURES

Based on the evaluation of the Company's disclosure controls and procedures by
Mr. Charles Smith, both the chief executive officer and chief accounting officer
of the company, as of a date within 90 days of the filing date of this quarterly
report, such officer has concluded that the Company's disclosure controls and
procedures are effective in ensuring that information required to be disclosed
by the Company in the reports that it files or submits under the Securities and
Exchange Act of 1934, as amended, is recorded, processed, summarized and
reported, within the time period specified by the Securities and Exchange
Commission's rules and forms.

There were no significant changes in the Company's internal controls or in other
factors that could significantly affect these controls subsequent to the date of
their evaluation, including any corrective actions with regard to significant
deficiencies and material weaknesses.


PART II - OTHER INFORMATION

Items No. 1, 2, 3, 4, 5 - Not applicable.

Item 6.  EXHIBITS AND REPORTS ON FORM 8-K

         a)  Exhibits
         27.1 Financial Data Schedule

         b) Reports on Form 8-K

         There were no reports on Form 8-K filed during the quarter for which
this report is filed.



<PAGE>

                                   SIGNATURES

     In accordance with the requirements of the Exchange Act, the registrant
has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.

                                           NATIONAL HEALTHCARE TECHNOLOGY, INC.


Date: August 8, 2003                       By:/s/ Charles Smith
                                           Charles Smith
                                           CEO, CFO



<PAGE>




                              FORM OF CERTIFICATION
                       PURSUANT TO RULE 13a-14 AND 15d-14
              UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED

                                  CERTIFICATION

I, Charles Smith, certify that:

1. I have reviewed this quarterly report on Form 10-QSB of National Healthcare
Technology, Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4.  The  registrant's   other  certifying  officer  and  I  am  responsible  for
establishing and maintaining  disclosure  controls and procedures (as defined in
Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

         (a)designed such disclosure controls and procedures to ensure that
material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly
during the period in which this quarterly report is being prepared;
         (b)evaluated the effectiveness of the registrant's disclosure controls
and procedures as of a date within 90 days of the filing date of this quarterly
report (the "Evaluation Date"); and
         (c)presented in this quarterly report our conclusions about the
effectiveness of the disclosure controls and procedures based on our evaluation
as of the Evaluation Date;

5. The registrant's other certifying officer and I
have disclosed, based on our most recent evaluation, to the registrant's
auditors and the audit committee of the registrant's board of directors (or
persons performing the equivalent functions):

         (a)all significant deficiencies in the design or operation of internal
controls which could adversely affect the registrant's ability to record,
process, summarize, and report financial data and have identified for the
registrant's auditors any material weaknesses in internal controls; and
         (b)any fraud, whether or not material, that involves management or
other employees who have a significant role in the registrant's internal
controls.

6. The registrant's other certifying officer and I have indicated in
this quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.

Date: August 8, 2003..................................... /s/ Charles Smith
                                                          Name:  Charles Smith
                                                          Title: President


<PAGE>





                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of National Healthcare Technology, Inc.
on Form 10-QSB for the period ended June 30, 2003 as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), each of the
undersigned, in the capacities and on the dates indicated below, hereby
certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906
of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:

1. The Report fully complies with the  requirements of Section 13(a) or 15(d) of
the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operation of the Company.

                                                        /s/  Charles Smith
                                                        Charles Smith, President
Dated: August 8, 2003





<PAGE>